Structure Therapeutics Inc. GPCR
We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors ("GPCRs"). These important receptors regulate numerous and diverse physiological and pathological processes. In fact, approximately one in every three marketed medicines targets GPCR-associated pathways for the treatment of various metabolic, cardiovascular and pulmonary disorders. By leveraging our world-class GPCR know-how, we are designing differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies that target this family of receptors.
GPCR is a depositary receipt: one GPCR stands for 3 shares of this company, per the cover page of its latest 10-K. The market cap and the multiples above are stated per receipt; the statements below, including EPS, are as filed and are per underlying share.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $225.3M | $108.8M | $70.1M | $36.2M | — |
| SG&A | $61.6M | $49.4M | $32.7M | $16.4M | — |
| Total operating expenses | $176.6M | $158.2M | $102.8M | $52.6M | — |
| Operating income | -$176.6M | -$158.2M | -$102.8M | -$52.6M | — |
| Pre-tax income | -$140.7M | -$122.2M | -$89.4M | -$51.3M | — |
| Income tax | $515.0K | $310.0K | $236.0K | $17.0K | — |
| Net income | -$141.2M | -$122.5M | -$89.6M | -$51.3M | — |
| EPS, basic | -0.80 | -0.78 | -0.81 | -5.51 | — |
| EPS, diluted | -0.80 | -0.78 | -0.81 | -5.51 | — |
| Shares, diluted (wtd. avg.) | 177.6M | 157.9M | 110.2M | 9.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $799.6M | $169.5M | $129.8M | $26.1M | $105.3M |
| Short-term investments | $646.6M | $714.0M | $337.5M | $64.8M | — |
| Total current assets | $1.57B | $891.2M | $473.6M | $93.1M | — |
| Property, plant and equipment | $6.7M | $3.5M | $3.2M | $1.0M | — |
| Total assets | $1.58B | $903.3M | $482.0M | $97.8M | — |
| Accounts payable | $13.9M | $8.0M | $4.7M | $6.0M | — |
| Total current liabilities | $63.3M | $36.0M | $24.7M | $13.0M | — |
| Total liabilities | $67.5M | $38.5M | $29.1M | $13.0M | — |
| Retained earnings | -$470.3M | -$329.1M | -$206.6M | -$117.0M | — |
| Total equity | $1.52B | $864.8M | $453.0M | -$115.1M | -$64.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$222.2M | -$116.6M | -$79.5M | -$46.1M | — |
| Depreciation and amortisation | $1.3M | $992.0K | $295.0K | $277.0K | — |
| Stock-based compensation | $29.0M | $18.8M | $8.2M | $2.5M | — |
| Capital expenditure | $3.6M | $1.3M | $2.2M | $155.0K | — |
| Investing cash flow | $89.8M | -$358.9M | -$268.3M | -$62.1M | — |
| Financing cash flow | $762.5M | $515.3M | $451.5M | $29.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-047740.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Net income | — | -$51.3M | -$89.6M | -$122.5M | -$141.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |